Overall rank by patents
#2,746
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
NxStage Medical, Inc.
USPTO PatentsView assignee record — 141 granted patents across 34 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
141
Total patents granted
34
CPC technology areas
14.3
Avg claims per patent
+162%
5-year filing velocity
The verdict
NxStage holds 141 US patents across 34 technology areas — rank #2,746 of 50,000 tracked assignees.
- #2,746
- of 50,000 US assignees by volume
- Top 7%
- by Innovation Score (54.8/100)
- 14.3
- avg claims per patent
- +162%
- filing velocity, last 5 yrs
Portfolio overview
NxStage Medical, Inc. has been granted 141 US utility patents between 2015 and 2025, placing NxStage Medical, Inc. at rank #2,746 across all assignees tracked by PlainPatent. This portfolio spans 34 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.3 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, NxStage Medical, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 54.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 102 grants, compared with 39 in the 2015–2019 window — a +162% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. NxStage Medical, Inc.'s 14.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 34 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark NxStage Medical, Inc. against peers pursuing similar technology classes.
How does NxStage compare?
Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Nxstage Medical ◀ 141
NxStage Medical, Inc.
141 patents
What this shows NxStage holds 141 patents — placing it at rank #2,746 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
NxStage's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
55 Top 7% higher than 93% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 2 | 1.4% |
| 2016 | 4 | 2.8% |
| 2017 | 12 | 8.5% |
| 2018 | 7 | 5.0% |
| 2019 | 14 | 9.9% |
| 2020 | 14 | 9.9% |
| 2021 | 16 | 11.3% |
| 2022 | 14 | 9.9% |
| 2023 | 15 | 10.6% |
| 2024 | 27 | 19.1% |
| 2025 | 16 | 11.3% |
Which technologies does NxStage Medical, Inc. patent most?
Top 15 of 34 technology areas
Patent Moat Analysis
Portfolio Volume Moderate
Tech Breadth Multi-domain
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does NxStage Medical, Inc. hold?
NxStage Medical, Inc. holds 141 US granted patents filed between 2015 and 2025, spanning 34 technology areas.
What is NxStage Medical, Inc.'s Innovation Score?
NxStage Medical, Inc. has an Innovation Score of 54.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does NxStage Medical, Inc. focus on?
NxStage Medical, Inc.'s top technology area is A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR) with 134 patents. The company has filed patents in 34 CPC subclasses total.
Is NxStage Medical, Inc.'s patent filing rate increasing or decreasing?
NxStage Medical, Inc.'s recent filing velocity is +162% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for NxStage Medical, Inc.'s patents?
NxStage Medical, Inc.'s patents average 14.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the NxStage Medical, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Learn More
Explore the patent dataset
A61M technology
NxStage Medical, Inc.'s primary CPC class — all holders and yearly trends
Top 50 patent holders
See where NxStage Medical, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
All federal data sources used on this page
- USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
- USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
- USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
- USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
- SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
- WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope
